César Sánchez

High Impact

Associate profesor

UAMS

COM | Internal Med Hem-Onc

20 h-index 143 pubs 2,481 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

César Sánchez investigates the molecular mechanisms and therapeutic strategies for various cancers, with a particular focus on breast cancer and gastrointestinal tumors. His research explores endocrine therapy resistance in breast cancer, including the role of ESR1 variants and preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy. He has also studied the efficacy of novel agents, such as the AKT inhibitor MK-2206, in combination with hormonal therapy for metastatic breast cancer. His work extends to other malignancies, including advanced gastric cancer, where he has been involved in clinical trials like KEYNOTE-859, and gastrointestinal stromal tumors, contributing to biomarker analysis in trials such as INTRIGUE.

Sánchez's research group at the University of Arkansas for Medical Sciences is active in preclinical cancer research. He has published extensively, with 143 total publications and over 2,481 citations, earning him recognition as a highly cited researcher. His collaborative network includes numerous colleagues at the University of Arkansas for Medical Sciences, such as Mamatha Gaddam and Ankur Varma, with whom he has co-authored multiple publications. His scholarly contributions are further evidenced by his h-index of 20.

Metrics

h-index: 20
Publications: 143
Citations: 2,481

Positions

Associate profesor 2001–present

Pontificia Universidad Catolica de Chile Escuela de Medicina hematologia oncologia ORCID
Associate profesor

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-11133-ACC CYTOKINE RELEASE SYNDROME-GUIDED RISK MODELS REDEFINE CARDIOTOXICITY SURVEILLANCE: OPTIMIZING DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND ADVERSE CARDIOVASCULAR EVENTS AFTER CAR-T THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
Long term outcomes of older patients with classical hodgkin lymphoma: an analysis of the Texas cancer registry (2025)

Annals of Hematology DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

Blood DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

Blood DOI OpenAlex
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial) (2025)

Blood DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Pricing, availability, and affordability of cancer medicines in 5 middle-income countries in South America. (2025)

Journal of Clinical Oncology 1 citation DOI OpenAlex
PREDICTORS OF ADVERSE CARDIOVASCULAR EVENTS AFTER CHIMERIC ANTIGEN T-CELL (CAR-T) THERAPY (2025)

Journal of the American College of Cardiology DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

Blood DOI OpenAlex
Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)

Blood DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma SouthWest Oncology Group Principal Investigator
276212 Open-label, Multicenter Phase 2 Study Evaluating the Efficacy&Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor T-cell Therapy in Patients w/ Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy CARGO Therapeutics, Inc. Principal Investigator